In part 4 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the Heart in Diabetes program and the World Congress on Insulin Resistance.
Yehuda Handelsman, MD, FACP, FNLA, MACE is a past president of the American College of Endocrinology and Medical Director of the Metabolic Institute of America in Tarzana, CA.
Transcript of this video segment:
Freed: You have a couple of conferences coming up. Can you give us a little bit of information about them?
Handelsman: Because of all this new information that you are asking me about regarding the new drugs, cardiologists now, all of a sudden, woke up saying. “Oh yeah, people with diabetes are at risk and we need to treat them!” So, it’s not only glucose. You did not treat them because it is only glucose. It is very clear now that people with diabetes have very high risk for cardiovascular disease and we need to understand the information of the new drugs. Should we give them SGLT2, should we give them GLP-1, should we give a TZD, when is it ok to give an insulin, for example, when is metformin as part of the combination O.K., when is it related to arrhythmia possibly? We do not know any of that. We have learned a lot. How much is it related to the kidney?
So, we developed a program; it’s called, “The Heart in Diabetes.” It’s going to be in Philadelphia at the Loews Hotel from July 13-15, I believe. The program is going to be two days and is going to be to examine all these questions. We partner, for example, with Circulation which is the Journal of The American Heart Association, looking at many of the aspects of diabetes that came to the journal. We are also looking to see the world of inflammation in relationship with diabetes and the heart and having some people look at the newer data on inflammation. Then we are going to look at your question exactly: How did these new studies impact guidelines? We are going to have a lecture on what are guidelines or recommendations for practice. We are going to have Sanjay Kaul who the FDA has been using to evaluate data to check those guidelines. Then somebody will talk about the AACE guidelines and the president of the ADA will talk about the ADA guidelines and somebody from ACC will talk about the American College of Cardiology’s guidelines. How is all this information impacting guidelines? Then, we are going to have a session on, based on all this information, how should we choose drugs. Should we use metformin first line or not? Should we use SGLT2 or GLP-1? So, we are going to have a head to head. We will also question whether blood pressure goals should be higher or lower. Should we have people like George Bakris who says it should be lower. We’ll have someone like Paul Wellman …. who says higher. All of this will be head to head and we’ll be looking at PCSK9 and the lipids – all of these for people with diabetes. Everything heart and diabetes – everything clinical.
In November, from the 29th to December 1st, we have the World Congress on Insulin Resistance – Diabetes and Cardiovascular Disease. This is going on its 16th year. This is now a much different program – it’s Tomorrow’s Clinical Science Today. We are looking at basic research, at obesity, and at the liver and heart, and how they interact and how the different drugs affect different organ statues. It’s a 3-day’s full impact which, this here, we are dedicating and honoring Gerald Reaven who passed away a few months ago. So, we are going to have a symposium in his memory and we renamed the award that we give after his name and there are lots of stuff that will we look at on insulin resistance, and obliviously then, on cardiovascular disease.